DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
IPO Year:
Exchange: NYSE
Website: davita.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/6/2024 | $133.00 | Equal Weight | Barclays |
8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS |
11/1/2022 | $97.00 → $72.00 | Buy → Hold | Deutsche Bank |
10/31/2022 | $117.00 → $74.00 | Buy → Neutral | UBS |
8/19/2022 | $106.00 → $117.00 | Buy | UBS |
6/21/2022 | $110.00 → $90.00 | Underperform | BofA Securities |
1/5/2022 | $114.00 → $125.00 | Hold | Truist Securities |
10/29/2021 | $113.00 → $111.00 | Sector Perform | RBC Capital |
10/13/2021 | $145.00 → $125.00 | Hold | Truist Securities |
9/10/2021 | $145.00 | Market Perform | Cowen & Co. |
3 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
10-Q - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
11-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
Kidney care leader provides free health screenings and resources to create awareness around kidney disease and open discussion around health care access DENVER, Sept. 17, 2024 /PRNewswire/ -- DaVita (NYSE:DVA), a leading provider of kidney care services, today announced the launch of its 2024 nationwide community health tour beginning September 24. The DaVita Health Tour is a mobile health screening and chronic disease education program supporting local communities across the country. Now entering its third year, the tour has provided thousands of free health screenings and equipped millions of community members with health education from coast to coast. The 2024 tour will feature an enhance
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
DENVER, Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.187 billion.Operating income was $506 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.59.Operating cas
DENVER, July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, August 6, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t
New York, United States, July 16, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global renal denervation devices market size was valued at USD 54.26 million in 2023. It is estimated to reach an expected value of USD 387 million by 2032, growing at a CAGR of 37.2% during the forecast period (2024–2032). A minimally invasive treatment called renal denervation is used to treat resistant hypertension. The primary contributors to the growth of the renal denervation devices market are the increasing elderly population, the rising prevalence of hypertension, and the procedure's long-lasting effects. Download Free Sample Report PDF @ https://straitsresearch.co
MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, today announced the extension of its pilot phase under its previously announced supply and collaboration agreement with DaVita Inc. (NYSE:DVA) until August 31, 2024. This program aims to pilot Aquadex® ultrafiltration therapy for adult patients suffering from congestive heart failure and related conditions in select U.S. markets. Today, DaVita serves as a leading provider of kidney care services, including acute and outpatient dialysis care for patients in-center and at home. The extension of the p
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),
DENVER, May 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at BofA Securities 2024 Health Care Conference on Tuesday, May 14th, 2024 at 5:00 pm Pacific Daylight Time. To view the live webcast, visit the BofA page and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality an
Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide. "Nurses are such
DENVER, May 2, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2024. "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence," said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: Consolidated revenues were $3.071 billion.Operating income was $484 million and adjusted operating income was $463 million.Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
TD Cowen analyst Gary Taylor maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $139 to $150.
DaVita Inc. (NYSE:DVA), a Colorado-based kidney dialysis provider, agreed to pay $34.5 million for allegedly paying kickbacks to a competitor for making referrals to DaVita Rx, a former subsidiary that provided pharmacy services for dialysis patients. DaVita also allegedly paid kickbacks to nephrologists and vascular access physicians to get patient referrals to DaVita's dialysis centers, the U.S. Department of Justice (DOJ) said on Thursday. The DOJ said DaVita violated the False Claims Act’s Anti-Kickback Statute, which prohibits providing any payments that are intended to induce referrals of patients or items or services covered by Medicare, Medicaid and other federally funded progr
- Bloomberg Citing DOJ
Investors demanded more clarity from German healthcare group Fresenius SE regarding its intentions to relinquish strategic control over dialysis group Fresenius Medical Care AG (NYSE:FMS). The investors’ call for transparency comes in the wake of Fresenius’s recent deconsolidation of Fresenius Medical Care, where the company still retains a 32% stake. Fresenius Medical Care faced significant challenges during the COVID-19 pandemic, including a higher mortality rate among dialysis patients and a shortage of nursing staff. “The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potent
Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $135 to $150.
In the latest quarter, 6 analysts provided ratings for DaVita (NYSE:DVA), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 3 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $137.83, with a high estimate of $150.00 and a low estimate of $130.00. Surpassing the previous average price targe
Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $133 to $150.
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously
Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously
UBS downgraded DaVita from Buy to Neutral and set a new price target of $74.00 from $117.00 previously
UBS resumed coverage of DaVita with a rating of Buy and set a new price target of $117.00 from $106.00 previously
BofA Securities reiterated coverage of DaVita with a rating of Underperform and set a new price target of $90.00 from $110.00 previously
Truist Securities reiterated coverage of DaVita with a rating of Hold and set a new price target of $125.00 from $114.00 previously
RBC Capital reiterated coverage of DaVita with a rating of Sector Perform and set a new price target of $111.00 from $113.00 previously
Truist Securities reiterated coverage of DaVita with a rating of Hold and set a new price target of $125.00 from $145.00 previously
Cowen & Co. initiated coverage of DaVita with a rating of Market Perform and set a new price target of $145.00
DENVER, Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.187 billion.Operating income was $506 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.59.Operating cas
DENVER, July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, August 6, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t
DENVER, May 2, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2024. "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence," said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: Consolidated revenues were $3.071 billion.Operating income was $484 million and adjusted operating income was $463 million.Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38
DENVER, April 17, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Thursday, May 2, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to th
DENVER, Feb. 13, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2023. "As we reflect on the past year, our 2023 financial performance highlighted the resilience of our business," said Javier Rodriguez, CEO of DaVita Inc. "The external challenges of recent years ultimately made us stronger, and with continued investment in our teammates, systems, and capabilities, we believe that we are well positioned for the years ahead. We enter 2024 with more confidence than we have had since the start of COVID in 2020." Financial and operating highlights for the quarter and year ended December 31, 2023: Consolidated revenu
DENVER, Jan. 23, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Tuesday, February 13, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, February 13, 2024Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, plea
DENVER, Aug. 3, 2023 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2023. "Over the first half of the year, DaVita has been focused on innovation in our clinical systems and driving operational improvements throughout our organization," said Javier Rodriguez, CEO of DaVita Inc. "Our second quarter performance reflects strong traction across those initiatives, putting us on a path to deliver strong clinical outcomes and financial results for the year." Financial and operating highlights for the quarter ended June 30, 2023: Consolidated revenues were $3.0 billion.Operating income was $405 million and adjusted operating income was
DENVER, July 13, 2023 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Thursday, August 3rd, 2023, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Thursday, August 3, 2023 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to lis
DENVER, May 8, 2023 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2023. "In the first quarter, we performed well on our key metrics and our results benefited from an improving macro environment," said Javier Rodriguez, CEO of DaVita Inc. "While some external uncertainty remains, 2023 is off to a strong start and the continuation of current trends would put us on a path to deliver strong results for the full year." Financial and operating highlights for the quarter ended March 31, 2023: Consolidated revenues were $2.873 billion.Operating income was $312 million and adjusted operating income was $352 million.Diluted earnings pe
DENVER, April 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 8, 2023, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, May 8, 2023 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide th
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),
Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide. "Nurses are such
DENVER, April 10, 2024 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors has appointed a new independent director, Dennis Pullin, to join the Board, effective April 10, 2024. "We're pleased to welcome Dennis to DaVita's board," said Pamela Arway, independent chair of the DaVita Inc. Board of Directors. "Given his depth of experience within the healthcare system, we're excited about the perspective Dennis will bring to the Board and look forward to his positive impact on our future growth and performance." Mr. Pullin is a recognized thought leader and advo
DENVER, July 13, 2023 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors appointed a new independent director, Wendy Schoppert, to join the Board, effective as of July 14, 2023. "We're pleased to welcome Wendy to DaVita's board," said Pam Arway, independent chair of the DaVita Inc. Board of Directors. "Her proven track record and broad corporate and board expertise will positively impact our governance and strategy." Ms. Schoppert has more than 30 years of leadership experience, including serving as Executive Vice President and Chief Financial Officer of S
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
Group Believes Board Has Disregarded Shareholders' Concerns by Appointing Solomon Trujillo as "Independent" Chairman Highlights Conflicting Financial Arrangements and Interlocks Among Board Members, Including Mr. Trujillo and Chief Executive Officer Marlow Hernandez Reiterates Demand that the Board Respect the Wishes of Shareholders by Making Necessary Leadership Changes or Reopening the Window to Nominate Director Candidates and Submit Proposals at 2023 Annual Meeting Elliot Cooperstone, Lewis Gold and Barry Sternlicht (collectively with certain of their affiliates, the "Group" or "we"), who recently resigned as members of the Board of Directors (the "Board") of Cano Health, Inc. ("C
DENVER, Sept. 13, 2022 /PRNewswire/ -- DaVita Inc. announced today that its Board of Directors appointed a new independent director, Adam H. Schechter, to join the Board, effective September 20, 2022. Mr. Schechter is the President, Chief Executive Officer and Chair of the Board of Directors of Laboratory Corporation of America Holdings ("Labcorp"), a leading global life sciences company with $16.1 billion in reported revenues in 2021. Mr. Schechter has served as President and CEO of LabCorp since November 2019, as a director since April 2013 and as Chair of the Board since M
DENVER, April 7, 2022 /PRNewswire/ -- DaVita Inc. announced today that its board of directors appointed a new independent director, Jason M. Hollar, to join the board, effective May 6, 2022. Mr. Hollar brings more than 25 years of financial experience spanning the health care, transportation, manufacturing and retail sectors to the board. Mr. Hollar currently serves as chief financial officer of Cardinal Health, Inc., a globally integrated health care services and products company with over $160 billion in 2021 revenues. Mr. Hollar leads financial activities across the Cardina
DENVER, Feb. 16, 2022 /PRNewswire/ -- DaVita Kidney Care today announced Dr. Mihran Naljayan as chief medical officer (CMO) of Home Modalities. Dr. Naljayan joined DaVita in 2016 and most recently served as vice president of clinical affairs within DaVita's home dialysis program. In that role, he created and led DaVita's home physician support network—a program that helps empower nephrologists to advocate for home dialysis with eligible patients. Since Dr. Naljayan joined DaVita, there has been a 35% increase in home hemodialysis and peritoneal dialysis treatments. He will continue to lead this initiative while expanding his scope as CMO of Home Modalities. "Dr. Naljayan is a relentless inno